Use of Predictive Biomarkers, Incorporating Chemotherapy—What Is Best When Using Immunotherapy in Advanced NSCLC?

Nivolumab Boosted Survival in Relapsed Mesothelioma

KEYNOTE-598: Dual PD-1 and CTLA-4 Checkpoint Blockade Confers No Therapeutic Benefit Beyond PD-1 Blockade Alone in PD-L1–Positive NSCLC

LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC

Genetically Tailored Treatment Approach Did Not Improve Survival in Stage II-III NSCLC

Envisioning A Tobacco-Free Generation

Controversy Regarding U.S. Marketing of New Heated Tobacco Product IQOS

Physician's Twitter Campaign Boosts UK Quit Smoking Efforts

Decade in Review: Changes in Smoking Behaviors Are Altering the Clinical Picture of Lung Cancer

Declaración de IASLC: dejar de fumar tras un diagnóstico de cáncer

Declaração da IASLC: cessação do tabagismo após o diagnóstico de câncer

IASLCからの宣言：癌診断後の禁煙